Quick Answer
Foghorn Therapeutics Inc. reported R&D Expense of $85.47 million for fiscal year 2025.
Foghorn Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $85.47M | -9.6% |
| 2024 | $94.53M | -13.8% |
| 2023 | $109.69M | +3.9% |
| 2022 | $105.62M | +31.5% |
| 2021 | $80.33M | +39.2% |
| 2020 | $57.72M | +30.1% |
| 2019 | $44.36M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.00M | -19.0% | -8.2% |
| June 30, 2025 | $21.79M | -8.4% | +0.8% |
| March 31, 2025 | $21.63M | -15.3% | -12.4% |
| September 30, 2024 | $24.69M | -6.0% | +3.7% |
| June 30, 2024 | $23.80M | -18.6% | -6.8% |
| March 31, 2024 | $25.53M | -14.8% | -2.7% |
| September 30, 2023 | $26.25M | -2.5% | -10.2% |
| June 30, 2023 | $29.25M | +12.6% | -2.5% |
- Foghorn Therapeutics Inc. showed a decrease of -9.6% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Foghorn Therapeutics Inc.’s r&d expense has grown by 92.7% (from $44.36 million to $85.47 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: